Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data AIM ImmunoTech Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.09
0.44
0.37
0.14
0.16
0.14
0.14
0.2
0.17
0.09
Research and development
5.11
4.1
4.78
4.65
5.72
7.67
6.99
10.9
6.2
3.92
General and administrative
7.68
6.57
6.2
7.04
8.65
8.67
13.1
21.1
13.7
7.7
Operating income
-13.8
-11.4
-11.5
-12.4
-15.2
-18.8
-19.9
-31.9
-19.8
-11.7
Interest expense
0.14
0.2
0.43
0.67
0.07
0.59
0.81
Other non-operating income
0.63
1.07
5.19
3.18
Pre-tax income
-14
Net income
-7.5
-8.26
-9.83
-9.4
-14.4
-19.1
-19.4
-29
-17.3
-14
EBITDA
-12.7
-10.5
-10.6
-11.7
-14.5
-18.2
-19.9
-31.9
-19.7
-11.6
EPS, basic
-1,506.00
-1,285.00
-974.48
-257.33
-44.88
-39.90
-39.90
-59.85
-30.92
-8.62
EPS, diluted
-1,506.00
-1,285.00
-974.48
-257.33
-44.88
-39.90
-39.90
-59.85
-30.92
-8.62
Shares, basic (weighted)
0
0.01
0.01
0.04
0.32
0.47
0.49
0.56
1.62
Shares, diluted (weighted)
0
0.01
0.01
0.04
0.32
0.47
0.48
0.49
0.56
1.62
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
2.41
1.41
0.3
1.47
38.5
32.1
27.1
5.44
1.7
2.99
Short-term investments
7.31
15.9
16.2
7.14
7.63
2.28
0.06
Receivables
0.02
0.24
0.04
0.03
1.68
1.18
0.01
Other current assets
0.31
0.61
0.88
0.85
0.18
0.3
0.46
0.3
0.2
0.24
Total current assets
6.94
3.51
3.8
10.4
40.3
50.2
36.3
14.6
4.18
3.3
Property, plant and equipment
9.51
8.59
7.78
7.12
6.47
4.05
0.2
0.13
0.11
0.07
Lease right-of-use assets
0.15
0.18
0.15
0.83
0.7
0.62
0.38
Intangible assets
0.87
0.86
0.91
1.15
1.5
1.97
1.94
2.31
2.59
1.66
Long-term investments
15.4
Other non-current assets
1.55
1.26
1.35
1.89
0.75
1.32
1.2
1.69
1.11
0.38
Total assets
18.9
14.2
13.8
20.8
64.6
57.7
40.5
19.4
8.61
5.78
Accounts payable
0.89
0.74
0.68
0.47
0.38
0.2
0.38
6.44
6.38
1.63
Accrued liabilities
1.55
1.97
1.01
0.4
0.44
0.44
0.81
1.99
0.61
0.8
Short-term debt
0.2
0.21
0.23
2.31
3.55
Total current liabilities
2.44
2.71
5.29
1.13
1.1
0.67
1.36
8.65
9.54
6.22
Long-term debt
1.84
2.32
2.1
1.88
0.93
Lease liabilities
0.11
0.13
0.11
0.66
0.5
0.4
0.17
Total liabilities
3.38
5.5
8.27
7.31
3.29
0.82
2.02
9.15
9.93
15.6
Total debt
2.52
2.32
2.11
2.81
4.48
Paid-in capital
316
317
324
340
403
417
418
419
426
431
Retained earnings
-301
-309
-319
-328
-342
-361
-381
-410
-427
-441
Other comprehensive income
-0.05
Shareholders' equity
15.5
8.7
5.58
13.4
61.3
56.9
38.5
10.2
-1.32
-9.78
Total equity
15.5
8.7
5.58
13.4
61.3
56.9
38.5
10.2
-1.32
-9.78
Total liabilities and equity
18.9
14.2
13.8
20.8
64.6
57.7
40.5
19.4
8.61
5.78
Shares outstanding
0.01
0.01
0.01
0.1
0.42
0.48
0.48
0.49
0.66
3.07
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-7.5
-8.26
-9.83
-9.4
-14.4
-19.1
-19.4
-29
-17.3
-14
Depreciation and amortization
1.12
0.95
0.86
0.74
0.67
0.66
0.04
0.04
0.04
0.04
Stock-based compensation
0.05
0.57
0.93
0.85
1.04
1.57
0.95
0.24
0.69
0.06
Change in receivables
-0.02
-1.07
-0.19
0.04
0.03
-0.04
0.49
1.18
Change in payables
-0.33
0.57
0.17
-0.21
-0.09
-0.19
0.18
6.07
-0.06
-1.71
Cash from operations
-7.38
-7.94
-10.6
-9.07
-10.4
-14
-16.1
-21.3
-14.9
-11
Capital expenditures
-0.16
-0.02
-0.05
-0.07
-0.02
-0.04
-0.09
-0.02
Purchases of investments
-5.78
-18.6
-22.5
-2.72
-1.59
-0.36
-0.09
Sales and maturities of investments
3.37
2.8
-0.83
10
22.3
10.1
0.18
0.66
Cash from investing
2.92
2.73
0.09
-6.15
-9.16
-0.63
11
-0.83
4.71
1.85
Debt repaid
-0.26
-0.34
-0.36
-0.12
Stock issued
4.74
2.42
5.07
15.3
61.2
13
Cash from financing
4.76
4.22
9.44
16.4
56.6
8.19
0.08
0.49
6.44
10.4
Net change in cash
0.29
-1
-1.11
1.17
37
-6.41
-5.04
-21.6
-3.74
1.28
Free cash flow
-7.54
-7.96
-10.7
-9.14
-10.4
-14
-16.2
-14.9
Interest paid
0.1
0.33
0.25
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.15 on November 11, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-11,724.0%
Operating income / revenue.
EBITDA margin
-11,687.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-15,021.0%
Net income / revenue.
Operating cash flow margin
-15,131.0%
Cash from operations / revenue.
Return on equity (ROE)
-184.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-112.1%
Net income / average total assets.
Return on invested capital (ROIC)
-600.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
2,885.0%
Research and development expense / revenue.
Stock-based pay / revenue
0.0%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
36.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-48.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-14.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-11.6%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-32.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-47.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-38.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
189.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
49.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
38.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.11x
Current assets / current liabilities.
Quick ratio
2.01x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.01x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.47x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
28.4%
Total debt / total assets.
Liabilities / assets
39.2%
Total liabilities / total assets.
Net debt
-$6.3M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.01
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.84
Cash from operations / diluted weighted shares.
Book value per share
$0.27
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
47.4x
Market cap / revenue.
P/B
0.58x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.75x
Market cap / tangible book value, when positive.
Earnings yield
-316.7%
Net income / market cap (the inverse of P/E).
What was AIM ImmunoTech Inc.'s revenue in fiscal 2025?
AIM ImmunoTech Inc. reported revenue of $88.0K for fiscal 2025, 48.2% lower than the year before.
Was AIM ImmunoTech Inc. profitable in fiscal 2025?
No. It reported a net loss of $14.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.